Company says data shared by GSK suggests ‘fundamental value’ of business no higher than offer
Unilever has said it will not increase its offer for GlaxoSmithKline’s consumer healthcare division above £50bn after investors and analysts balked at the risk of it pulling off a large merger.
Data shared by GSK suggested the “fundamental value” of the business was no higher than £50bn, Unilever said after the stock market closed on Wednesday.
